APA (7th ed.) Citation

Cimino-Mathews, A., Lee, M., Lee, J., Trepel, J. B., Yuno, A., Lampert, E. J., . . . An, D. Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Cimino-Mathews, Ashley, Min-Jung Lee, Jung-Min Lee, Jane B. Trepel, Akira Yuno, Erika J. Lampert, Joo Sang Lee, Jayakumar Nair, and Daniel An. Clinical Outcomes of Prexasertib Monotherapy in Recurrent BRCA Wild-type High-grade Serous Ovarian Cancer Involve Innate and Adaptive Immune Responses. BMJ Publishing Group.

MLA (9th ed.) Citation

Cimino-Mathews, Ashley, et al. Clinical Outcomes of Prexasertib Monotherapy in Recurrent BRCA Wild-type High-grade Serous Ovarian Cancer Involve Innate and Adaptive Immune Responses. BMJ Publishing Group.